Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CHINOOK THERAPEUTICS, INC. (KDNY)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Mar-05-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Mar-05-22 |
| | 10-Q | 10-Q | 8-K | 10-K | 10-Q | 10-Q | 10-Q | 8-K |
| Revenues [+] | 1.0 | 1.8 | 50.9 | 0.5 | 2.5 | 0.4 | 2.7 | 26.3 |
| Royalties | | | 50.9 | | | | | 26.3 |
| Revenue growth | 141.1% | -32.2% | 93.8% | -99.0% | 62425.0% | 1129.4% | 668.4% | |
| Cost of goods sold | 0.0 | 0.0 | 100.5 | 7.3 | 7.7 | 0.0 | 0.0 | 48.8 |
| Gross profit | 1.0 | 1.8 | -49.6 | -6.8 | -5.2 | 0.4 | 2.7 | -22.5 |
| Gross margin | 100.0% | 100.0% | -97.4% | -1319.5% | -209.5% | 100.0% | 100.0% | -85.8% |
| Selling, general and administrative [+] | | | 11.4 | 9.8 | 10.0 | | | 7.9 |
| General and administrative | 0.0 | 0.0 | 11.4 | 9.8 | 10.0 | 0.0 | 0.0 | 7.9 |
| Research and development | | | | 43.0 | 42.0 | | | |
| Equity in earnings | | | | -0.8 | 0.0 | | | |
| Other operating expenses | 1.0 | 1.8 | | | | 0.4 | 2.7 | |
| EBITDA [+] | 1.5 | 0.9 | -61.0 | -59.8 | -56.8 | 0.8 | 0.9 | -30.4 |
| EBITDA growth | 87.5% | 0.0% | 100.7% | -613.1% | 86.9% | -102.3% | -102.5% | |
| EBITDA margin | 148.8% | 49.2% | -119.9% | -11684.2% | -2271.4% | 191.4% | 33.4% | -115.7% |
| Depreciation | 1.1 | 0.5 | | 0.4 | 0.4 | 0.4 | 0.5 | |
| EBITA | 0.4 | 0.4 | -61.0 | -60.2 | -57.2 | 0.4 | 0.4 | -30.4 |
| EBITA margin | 43.0% | 23.7% | -119.9% | -11763.1% | -2288.6% | 102.6% | 15.9% | -115.7% |
| Amortization of intangibles | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
| EBIT [+] | 0.0 | 0.0 | -61.4 | -60.7 | -57.7 | 0.0 | 0.0 | -30.8 |
| EBIT growth | | | 99.3% | -659.7% | 85.5% | -100.0% | -100.0% | |
| EBIT margin | 0.0% | 0.0% | -120.7% | -11847.7% | -2305.8% | 0.0% | 0.0% | -117.4% |
| Interest income | 3.7 | 3.1 | | 4.8 | | 0.8 | -0.1 | |
| Interest income | 3.7 | 3.1 | | 4.8 | | 0.8 | -0.1 | |
| Other income (expense), net [+] | -72.6 | -61.4 | 1.2 | -4.9 | 1.7 | -36.7 | -30.8 | -0.9 |
| Other | | | | | 1.7 | | | |
| Pre-tax income | -69.0 | -58.3 | -60.2 | -60.7 | -56.0 | -35.9 | -30.9 | -31.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 4.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -66.9 | -60.2 | -60.2 | -62.6 | -56.0 | -37.6 | -31.7 | -31.7 |
| Net margin | -6641.3% | -3292.0% | -118.3% | -12217.6% | -2238.3% | -9006.7% | -1174.8% | -120.7% |
| |
| Basic EPS [+] | ($0.94) | ($0.85) | ($0.85) | ($0.97) | ($0.83) | ($0.61) | ($0.54) | ($0.54) |
| Growth | 53.9% | 56.7% | 56.7% | -687.4% | 20.2% | -37.4% | -38.5% | |
| Diluted EPS [+] | ($0.94) | ($0.85) | ($0.85) | ($0.97) | ($0.83) | ($0.61) | ($0.54) | ($0.54) |
| Growth | 53.9% | 56.7% | 56.7% | -687.4% | 20.2% | -37.4% | -38.5% | |
| |
| Shares outstanding (basic) [+] | 71.6 | 70.7 | 70.7 | 64.4 | 67.8 | 62.0 | 58.3 | 58.3 |
| Growth | 15.5% | 21.2% | 21.2% | 41.1% | 51.8% | 41.3% | 38.5% | |
| Shares outstanding (diluted) [+] | 71.6 | 70.7 | 70.7 | 64.4 | 67.8 | 62.0 | 58.3 | 58.3 |
| Growth | 15.5% | 21.2% | 21.2% | 41.1% | 51.8% | 41.3% | 38.5% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|